Geode Capital Management
ALLO icon

Geode Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Geode Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1M Buy
4,124,178
+191,268
+5% +$383K ﹤0.01% 2375
2025
Q4 		$5.39M Buy
3,932,910
+99,025
+3% +$131K ﹤0.01% 2726
2025
Q3 		$4.75M Buy
3,833,885
+39,058
+1% +$46.6K ﹤0.01% 2808
2025
Q2 		$4.29M Buy
3,794,827
+435,389
+13% +$579K ﹤0.01% 2806
2025
Q1 		$4.91M Buy
3,359,438
+126,820
+4% +$239K ﹤0.01% 2663
2024
Q4 		$6.89M Buy
3,232,618
+5,514
+0.2% +$13.6K ﹤0.01% 2573
2024
Q3 		$9.04M Buy
3,227,104
+407,070
+14% +$1.09M ﹤0.01% 2446
2024
Q2 		$6.57M Buy
2,820,034
+448,700
+19% +$1.32M ﹤0.01% 2580
2024
Q1 		$10.6M Buy
2,371,334
+36,139
+2% +$151K ﹤0.01% 2291
2023
Q4 		$7.5M Buy
2,335,195
+263,842
+13% +$748K ﹤0.01% 2487
2023
Q3 		$6.57M Buy
2,071,353
+243,571
+13% +$1.07M ﹤0.01% 2502
2023
Q2 		$9.08M Buy
1,827,782
+78,538
+4% +$425K ﹤0.01% 2340
2023
Q1 		$8.64M Buy
1,749,244
+42,784
+3% +$274K ﹤0.01% 2348
2022
Q4 		$10.7M Buy
1,706,460
+77,793
+5% +$720K ﹤0.01% 2222
2022
Q3 		$17.6M Buy
1,628,667
+160,061
+11% +$2.18M ﹤0.01% 1832
2022
Q2 		$16.7M Buy
1,468,606
+207,355
+16% +$1.84M ﹤0.01% 1879
2022
Q1 		$11.5M Sell
1,261,251
-117,652
-9% -$1.23M ﹤0.01% 2260
2021
Q4 		$20.6M Buy
1,378,903
+118,850
+9% +$2.1M ﹤0.01% 1946
2021
Q3 		$32.4M Buy
1,260,053
+31,972
+3% +$759K ﹤0.01% 1640
2021
Q2 		$32M Buy
1,228,081
+155,250
+14% +$4.43M ﹤0.01% 1665
2021
Q1 		$37.9M Buy
1,072,831
+83,925
+8% +$2.83M 0.01% 1447
2020
Q4 		$25M Buy
988,906
+46,980
+5% +$1.53M ﹤0.01% 1582
2020
Q3 		$35.5M Buy
941,926
+35,849
+4% +$1.35M 0.01% 1108
2020
Q2 		$38.8M Buy
906,077
+170,840
+23% +$6.18M 0.01% 1033
2020
Q1 		$14.3M Buy
735,237
+56,183
+8% +$1.34M ﹤0.01% 1514
2019
Q4 		$17.6M Buy
679,054
+25,869
+4% +$712K ﹤0.01% 1645
2019
Q3 		$17.8M Buy
653,185
+239,671
+58% +$6.83M ﹤0.01% 1562
2019
Q2 		$11.1M Buy
413,514
+102,625
+33% +$2.86M ﹤0.01% 1875
2019
Q1 		$8.99M Sell
310,889
-8,179
-3% -$237K ﹤0.01% 1971
2018
Q4 		$8.59M Buy
+319,068
New +$8.48M ﹤0.01% 1872

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management's ALLO Position: Q1 2026 in Review

Geode Capital Management increased its Allogene Therapeutics (ALLO) stake by 4.9% in Q1 2026, buying an estimated $383K and bringing the position to 4,124,178 shares worth $10.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

Geode Capital Management first reported a position in ALLO in Q4 2018 and has held it in 30 quarters since. The position peaked at $38.8M in Q2 2020. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Geode Capital Management held 4,124,178 shares of Allogene Therapeutics worth $10.1M as of Q1 2026.
  • Geode Capital Management bought 191,268 Allogene Therapeutics shares in Q1 2026, an estimated $383K.
  • Allogene Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2375 holding.
  • Geode Capital Management first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • Geode Capital Management's Allogene Therapeutics position peaked at $38.8M in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.